Nektar Therapeutics (NKTR)

Nektar Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	41.03	44.25	35.28	88.23	25.22	198.96
Short-Term Investments	229.18	210.97	268.34	416.75	708.74	862.94
Cash & Short-Term Investments	270.21	255.23	303.62	504.98	733.96	1,062
Cash Growth	10.52%	-15.94%	-39.88%	-31.20%	-30.88%	-19.85%
Accounts Receivable	-	-	1.21	5.98	22.49	38.89
Other Receivables	1.29	1.61	1.05	2.42	1.4	5.1
Receivables	1.29	1.61	2.25	8.4	23.89	43.99
Inventory	-	-	16.1	19.2	15.8	15.29
Prepaid Expenses	2.36	2.51	4.41	5.99	-	-
Other Current Assets	7.5	1.95	4.33	7.4	21.93	16.83
Total Current Assets	281.36	261.29	330.7	545.97	795.58	1,138
Property, Plant & Equipment	10	11.82	36.86	85.89	177.54	186.14
Long-Term Investments	4.84	26.09	25.83	-	64.83	136.66
Goodwill	-	-	-	76.5	76.5	76.5
Other Long-Term Assets	5.16	4.65	4.64	2.25	2.74	1.46
Total Assets	301.35	303.85	398.03	710.6	1,117	1,539
Accounts Payable	15.56	11.56	9.85	12.98	9.75	22.14
Accrued Expenses	25.45	27.21	19.14	28.85	58.01	79.73
Current Portion of Leases	22.18	19.87	19.26	18.67	17.44	13.92
Other Current Liabilities	3.15	2.77	3.02	7.71	-	-
Total Current Liabilities	66.34	61.4	51.27	68.2	85.2	115.78
Long-Term Debt	75.16	91.78	112.63	155.38	195.43	200.34
Long-Term Leases	69.73	82.7	98.52	112.83	125.74	136.37
Other Long-Term Liabilities	5.03	7.24	4.64	7.55	31.32	8.98
Total Liabilities	216.26	243.11	267.05	343.96	437.68	461.47
Common Stock	0	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	3,809	3,660	3,608	3,575	3,517	3,389
Retained Earnings	-3,724	-3,596	-3,477	-3,201	-2,833	-2,309
Treasury Stock	-	-3	-	-	-	-
Comprehensive Income & Other	0.06	0.06	0.08	-6.91	-4.16	-2.3
Shareholders' Equity	85.09	60.74	130.99	366.64	679.51	1,077
Total Liabilities & Equity	301.35	303.85	398.03	710.6	1,117	1,539
Total Debt	167.08	194.34	230.4	286.87	338.6	350.63
Net Cash (Debt)	103.13	74.76	99.04	218.1	460.18	847.93
Net Cash Growth	140.16%	-24.52%	-54.59%	-52.61%	-45.73%	-24.55%
Net Cash Per Share	6.75	5.45	7.82	17.48	37.66	71.22
Filing Date Shares Outstanding	20.34	12.41	12.24	12.62	12.42	12.15
Total Common Shares Outstanding	19.65	12.39	12.76	12.57	12.36	12.01
Working Capital	215.02	199.89	279.43	477.76	710.38	1,022
Book Value Per Share	4.33	4.90	10.27	29.17	54.96	89.73
Tangible Book Value	85.09	60.74	130.99	290.14	603.01	1,001
Tangible Book Value Per Share	4.33	4.90	10.27	23.08	48.77	83.36
Buildings	-	3.88	43.18	74.89	97.39	92.98
Machinery	-	15.2	61.83	79.76	104	100.47
Construction In Progress	-	0.25	0.74	2.53	7.16	4.7

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q